Market Cap 459.94M
Revenue (ttm) 0.00
Net Income (ttm) -258.75M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,727,200
Avg Vol 2,091,866
Day's Range N/A - N/A
Shares Out 108.22M
Stochastic %K 91%
Beta 0.48
Analysts Sell
Price Target $7.65

Company Profile

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases in the United States. It develops vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inher...

Industry: Biotechnology
Sector: Healthcare
Phone: 609 659 8001
Address:
9 Cedarbrook Drive, Cranbury, United States
SteveJohnsonis
SteveJohnsonis Feb. 26 at 4:33 AM
0 · Reply
Doccjc62
Doccjc62 Feb. 26 at 4:19 AM
0 · Reply
Doccjc62
Doccjc62 Feb. 26 at 4:18 AM
0 · Reply
Stephanovich7654568
Stephanovich7654568 Feb. 26 at 3:05 AM
0 · Reply
Stephanovich7654568
Stephanovich7654568 Feb. 26 at 2:46 AM
0 · Reply
Stephanovich7654568
Stephanovich7654568 Feb. 26 at 2:26 AM
0 · Reply
buymoremakemore
buymoremakemore Feb. 26 at 2:09 AM
1 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Feb. 26 at 1:18 AM
0 · Reply
defion
defion Feb. 25 at 11:34 PM
0 · Reply
darntootin
darntootin Feb. 25 at 10:43 PM
0 · Reply
Latest News on RCKT
Rocket Refocuses Pipeline As Gene Therapy Sentiment Sours

Jul 25, 2025, 3:02 PM EDT - 7 months ago

Rocket Refocuses Pipeline As Gene Therapy Sentiment Sours


SteveJohnsonis
SteveJohnsonis Feb. 26 at 4:33 AM
0 · Reply
Doccjc62
Doccjc62 Feb. 26 at 4:19 AM
0 · Reply
Doccjc62
Doccjc62 Feb. 26 at 4:18 AM
0 · Reply
Stephanovich7654568
Stephanovich7654568 Feb. 26 at 3:05 AM
0 · Reply
Stephanovich7654568
Stephanovich7654568 Feb. 26 at 2:46 AM
0 · Reply
Stephanovich7654568
Stephanovich7654568 Feb. 26 at 2:26 AM
0 · Reply
buymoremakemore
buymoremakemore Feb. 26 at 2:09 AM
1 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Feb. 26 at 1:18 AM
0 · Reply
defion
defion Feb. 25 at 11:34 PM
0 · Reply
darntootin
darntootin Feb. 25 at 10:43 PM
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Feb. 25 at 10:32 PM
$RCKT WHY ARE THERE NO ROCKET MEMES HERE?!
1 · Reply
geegor
geegor Feb. 25 at 8:37 PM
$RCKT at current price: --Would be highest close since May 23, 2025, when it closed at $6.27 --On pace for largest % increase since Feb. 24, 2026, when it rose 6.52% --Currently up 12 of the past 13 days --Currently up 9 consecutive days; up 33.49% over this period --Longest winning streak since Aug. 31, 2018, when it rose for 12 straight trading days --Best 9 day stretch since the 9 days ending Oct. 14, 2025, when it rose 35.13% --Up 24.28% month-to-date; on pace for best month since July 2025, when it rose 24.49% --Up 23.22% YTD --Down 93.87% from its all-time closing high of $70.60 on July 24, 2015 --Down 54.57% from its 52-week closing high of $9.52 on Feb. 26, 2025 --Up 85.62% from its 52-week closing low of $2.33 on May 27, 2025 --Traded as high as $4.45; highest intraday level since Oct. 15, 2025, when it hit $4.51 --Up 4.71% at today's intraday high All data as of 2:15:20 PM ET Source: Dow Jones Market Data, FactSet DJ Newswires Feb 25, 2026 14:26 ET (19:26 GMT)
0 · Reply
Stockseeking
Stockseeking Feb. 25 at 8:16 PM
$RCKT Earning stuff does not matter at this moment since the universe knows they don't have commercial products yet, they will have one in a month and then the next ER matters. Sure, management will have a very positive tone about the coming FDA decision. They already mentioned that review has been on a smooth path, regular information requests and even post-approval commitment. 4.50 by Friday and next week >5.0. Approval 7-8.
0 · Reply
buymoremakemore
buymoremakemore Feb. 25 at 8:01 PM
$RCKT This is holding really nicely! Let's go!!!!
0 · Reply
MoneyTalksBullShitsWalks
MoneyTalksBullShitsWalks Feb. 25 at 8:01 PM
$RCKT any dovish signal for KRESALDI CMC CRL, words such as "on-track" or touting any "positive progress" market will react with enthusiasm. I'd say, an uplift by 5% of probability-of-success providing more confidence to the shareholders.
0 · Reply
TraderGOAT
TraderGOAT Feb. 25 at 7:47 PM
$RCKT Just started doing dd on sllid upcoming biotech catalysts with this PDUFA on deck. Would have been great to buy this at 3 weeks ago 🤙
2 · Reply
SusQSmallMouth
SusQSmallMouth Feb. 25 at 7:04 PM
$RCKT where is the PR on earnings announcement?
0 · Reply
KassYanis
KassYanis Feb. 25 at 6:51 PM
$RCKT healthy dip before the rip!
1 · Reply
Stockseeking
Stockseeking Feb. 25 at 5:36 PM
$RCKT One thing for sure in tomorrow's ER, reinforce review is approaching the end including post-approval activities, ...
0 · Reply
buymoremakemore
buymoremakemore Feb. 25 at 4:41 PM
$RCKT I think earnings tomorrow might push stock even higher. I mean after all dannon hold is lifted. They will probably reiterate a trial happening soon and maybe even they met with FDA already. I think as long as there arent any big surprises with net loss we should be fine.
0 · Reply
Plowmaster
Plowmaster Feb. 25 at 4:16 PM
$RCKT earnings premarket tomorrow Numbers are mostly background as long as nothing crazy pops really what we’re looking for is any color on the March 28 PDUFA how the FDA interactions are going and any hints or Easter eggs on other trials or pipeline stuff that could move the stock more than the raw numbers, lets go Rocket!
0 · Reply
Sciencefiction666
Sciencefiction666 Feb. 25 at 2:56 PM
$RCKT Does anyone know what time earnings come out?
1 · Reply